Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Short term Debt (2016 - 2025)

Haemonetics has reported Short term Debt over the past 16 years, most recently at $304.7 million for Q4 2025.

  • Quarterly results put Short term Debt at $304.7 million for Q4 2025, up 5904.85% from a year ago — trailing twelve months through Dec 2025 was $304.7 million (up 5904.85% YoY), and the annual figure for FY2025 was $303.6 million, up 2867.62%.
  • Short term Debt for Q4 2025 was $304.7 million at Haemonetics, roughly flat from $304.3 million in the prior quarter.
  • Over the last five years, Short term Debt for HAE hit a ceiling of $304.7 million in Q4 2025 and a floor of $5.1 million in Q4 2024.
  • Median Short term Debt over the past 5 years was $15.4 million (2021), compared with a mean of $92.3 million.
  • Biggest five-year swings in Short term Debt: tumbled 94.5% in 2023 and later surged 5904.85% in 2025.
  • Haemonetics' Short term Debt stood at $82.7 million in 2021, then crashed by 87.97% to $9.9 million in 2022, then surged by 38.06% to $13.7 million in 2023, then plummeted by 63.05% to $5.1 million in 2024, then surged by 5904.85% to $304.7 million in 2025.
  • The last three reported values for Short term Debt were $304.7 million (Q4 2025), $304.3 million (Q3 2025), and $303.9 million (Q2 2025) per Business Quant data.